Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

295 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Pemetrexed in Recurrent or Progressive Central Nervous System Lymphoma: A Phase I Multicenter Clinical Trial.
Dietrich J, Versmee L, Drappatz J, Eichler AF, Nayak L, Norden A, Wong E, Pisapia MR, Jones SS, Gordon AB, Chabner BA, Hochberg F, Batchelor TT. Dietrich J, et al. Among authors: nayak l. Oncologist. 2020 Sep;25(9):747-e1273. doi: 10.1634/theoncologist.2020-0489. Epub 2020 Jul 1. Oncologist. 2020. PMID: 32520407 Free PMC article. Clinical Trial.
Atypical and anaplastic meningiomas treated with bevacizumab.
Nayak L, Iwamoto FM, Rudnick JD, Norden AD, Lee EQ, Drappatz J, Omuro A, Kaley TJ. Nayak L, et al. J Neurooncol. 2012 Aug;109(1):187-93. doi: 10.1007/s11060-012-0886-4. Epub 2012 Apr 29. J Neurooncol. 2012. PMID: 22544653
Update on bevacizumab and other angiogenesis inhibitors for brain cancer.
Rinne ML, Lee EQ, Nayak L, Norden AD, Beroukhim R, Wen PY, Reardon DA. Rinne ML, et al. Among authors: nayak l. Expert Opin Emerg Drugs. 2013 Jun;18(2):137-53. doi: 10.1517/14728214.2013.794784. Epub 2013 May 14. Expert Opin Emerg Drugs. 2013. PMID: 23668489 Review.
Retrospective study of carmustine or lomustine with bevacizumab in recurrent glioblastoma patients who have failed prior bevacizumab.
Rahman R, Hempfling K, Norden AD, Reardon DA, Nayak L, Rinne ML, Beroukhim R, Doherty L, Ruland S, Rai A, Rifenburg J, LaFrankie D, Alexander BM, Huang RY, Wen PY, Lee EQ. Rahman R, et al. Among authors: nayak l. Neuro Oncol. 2014 Nov;16(11):1523-9. doi: 10.1093/neuonc/nou118. Epub 2014 Jun 23. Neuro Oncol. 2014. PMID: 24958095 Free PMC article.
Phase 2 trial of high-dose rituximab with high-dose cytarabine mobilization therapy and high-dose thiotepa, busulfan, and cyclophosphamide autologous stem cell transplantation in patients with central nervous system involvement by non-Hodgkin lymphoma.
Chen YB, Batchelor T, Li S, Hochberg E, Brezina M, Jones S, Del Rio C, Curtis M, Ballen KK, Barnes J, Chi AS, Dietrich J, Driscoll J, Gertsner ER, Hochberg F, LaCasce AS, McAfee SL, Spitzer TR, Nayak L, Armand P. Chen YB, et al. Among authors: nayak l. Cancer. 2015 Jan 15;121(2):226-33. doi: 10.1002/cncr.29023. Epub 2014 Sep 9. Cancer. 2015. PMID: 25204639 Free PMC article. Clinical Trial.
Phase II trial of triple tyrosine kinase receptor inhibitor nintedanib in recurrent high-grade gliomas.
Norden AD, Schiff D, Ahluwalia MS, Lesser GJ, Nayak L, Lee EQ, Rinne ML, Muzikansky A, Dietrich J, Purow B, Doherty LM, LaFrankie DC, Pulverenti JR, Rifenburg JA, Ruland SF, Smith KH, Gaffey SC, McCluskey C, Ligon KL, Reardon DA, Wen PY. Norden AD, et al. Among authors: nayak l. J Neurooncol. 2015 Jan;121(2):297-302. doi: 10.1007/s11060-014-1631-y. Epub 2014 Oct 22. J Neurooncol. 2015. PMID: 25338318 Clinical Trial.
295 results